Multilevel temperature-controlled radiofrequency for obstructive sleep apnea: Extended follow-up DAVID L. STEWARD, MD, EDWARD M. WEAVER, Milwaukee, Wisconsin
and B. TUCKER WOODSON,
OBJECTIVE: To determine long-term effectiveness of multilevel (tongue and palate) temperature-controlled radiofrequency tissue ablation (TCRFTA) for patients with obstructive sleep apnea syndrome (OSAS). STUDY DESIGN AND SETTING: Prospective, 2-institution case series. Twenty-nine subjects with mild to moderate OSAS and who were at least 1 year from completion of multilevel TCRFTA were included, representing a subset of subjects who were enrolled in a previously published controlled trial. Exclusion criteria for this extended follow-up study included any additional treatment for OSAS after completion of TCRFTA. RESULTS: Median follow-up was 23 months. Daytime sleepiness and OSAS-related quality of life were significantly improved at extended follow-up (both P < 0.001). Median reaction time testing and apnea-hypopnea index (AHI) were also significantly improved at long-term follow-up (P ⴝ 0.03 and 0.01). Body mass index was unchanged (P ⴝ 0.94). CONCLUSIONS: Multilevel TCRFTA treatment of mild to moderate OSAS resulted in prolonged improvement in daytime somnolence, OSAS-related quality of life, psychomotor vigilance, and AHI in this group of subjects at extended follow-up. (Otolaryngol Head Neck Surg 2005;132:630-635.)
From the Department of Otolaryngology–Head and Neck Surgery, University of Cincinnati, Cincinnati, OH (Dr Steward), the Department of Otolaryngology–Head and Neck Surgery, University of Washington, Seattle, WA (Dr Weaver), and the Department of Otolaryngology–Head and Neck Surgery, Medical College of Wisconsin, Milwaukee, WI (Dr Woodson). Data collection was supported in part by a research grant from Gyrus-ENT. Dr Weaver was supported by the Robert Wood Johnson Clinical Scholars Program during the development of the parent study. Dr Weaver is currently supported by a career development award (HL068849) from the National Heart, Lung, and Blood Institute and by a career development scholars’ award from the American Geriatrics Society, the Hartford Foundation, and the Atlantic Philanthropies. Presented at the Annual Meeting of the American Academy of Otolaryngology–Head and Neck Surgery, New York, NY, September 17-20, 2004. Reprint requests: David L. Steward, MD, Department of Otolaryngology–Head and Neck Surgery, ML 0528, University of Cincinnati, Cincinnati, OH 45267-0528; e-mail, [email protected]
0194-5998/$30.00 Copyright © 2005 by the American Academy of Otolaryngology–Head and Neck Surgery Foundation, Inc. doi:10.1016/j.otohns.2004.11.013
Cincinnati, Ohio, Seattle, Washington, and
sleep apnea syndrome (OSAS) is thought to affect between 2% and 4% of adults, resulting in significant morbidity and mortality.1 Morbidity results primarily from cardiovascular disease; quality of life deficits; and performance deficits caused by loss of alertness and daytime somnolence, increasing risk for motor vehicle accidents.2 However, successful treatment of OSAS with mechanical devices or surgery has been shown to ameliorate these risks of OSAS.3,4 Nasal continuous positive airway pressure (CPAP), a mechanical device, is an efficacious treatment for severe OSAS. However, long-term effectiveness is limited by inadequate treatment adherence in many patients, especially those with milder OSAS.5 Other devices such as oral appliances are less efficacious than CPAP, and effectiveness is also dependent upon nightly adherence.6 Surgical management of OSAS has the advantage of not being dependent upon nightly use of a device but often produces incomplete correction or relapse of symptoms over time.7 Further, traditional operations are associated with significant perioperative morbidity. Temperature-controlled radiofrequency tissue ablation (TCRFTA) of the tongue base and palate has been shown to improve OSAS in a randomized sham-placebo– controlled trial with minimal morbidity.8 Extended follow-up of patients undergoing tongue base TCRFTA for OSAS demonstrated persistent improvements in measures of general health status (short form36) and daytime sleepiness.9 This study was designed to assess the long-term effectiveness of multilevel (tongue and palate) TCRFTA to improve quality of life, symptoms, reaction time, and physiology for patients with mild to moderate OSAS. Our hypothesis is that TCRFTA treatment provides long-term improvements in these outcomes, using validated measures. MATERIALS AND METHODS Study Design This was a prospective 2-institutional case series with extended follow-up (minimum, 1 year) involving subjects treated with multilevel (tongue and palate) TCRFTA as part of a previously published randomized, CPAP and sham-placebo controlled trial.8 This study differs from previous publications involving these patients in that it studies long-term outcomes of TCRFTA
Otolaryngology– Head and Neck Surgery Volume 132 Number 4
STEWARD et al 631
treatment, whereas previous publications reported on only short-term outcomes.
Tongue-base treatments consisted of 600 to 1100 J, delivered to 1 to 3 sites (nonoverlapping).8
Subjects Twenty-nine subjects with mild to moderate OSAS (apnea-hypopnea index [AHI] between 5 and 40) and who were at least 1 year from completion of multilevel TCRFTA were included (minimum, 3 total treatment sessions, including at least 1 to tongue base and 1 to palate). This represents a subset of subjects who were enrolled in the original trial and included those who were originally randomized to TCRFTA or those who elected to cross over to active TCRFTA after completion of sham placebo or nasal CPAP therapy. Detailed inclusion criteria for the original study were published elsewhere.8 Exclusion criteria for this long-term follow-up study included any additional treatment for OSAS after completion of multilevel TCRFTA (nasal CPAP, surgery, and so on). All potentially eligible subjects were offered inclusion in this study. Twentynine of 46 potentially eligible subjects agreed to participate (63%). Of those 17 potentially eligible subjects who did not participate, 5 could not be located (moved or bad phone number), 4 refused, and 8 reported that they were too busy or missed scheduled appointments and didn’t follow-up despite multiple phone calls. Three patients were excluded because of additional treatment after completion of TCRFTA (2 CPAP, 1 surgery). Three additional patients undergoing crossover treatment were excluded because they underwent fewer than 3 total treatment sessions or were not multilevel (both tongue and palate). Crossover treatment was not part of the original protocol, and decisions regarding treatment after original protocol completion were individualized such that not all patients underwent crossover treatment with TCRFTA. This study was designed and performed with approval from local institutional review boards and in compliance with the Health Insurance Portability and Accountability Act. All subjects provided informed consent.
Outcomes The primary outcome measures were chosen to represent meaningful measurements of quality of life, daytime sleepiness, and reaction times (psychomotor vigilance). Surrogate outcome measures, including sleep respiratory parameters, were secondary outcomes.10 Lowest saturation did not improve with TCRFTA in the parent trial, so long-term results are not shown (no improvement). OSAS-specific quality of life was measured with the validated Functional Outcomes of Sleep Questionnaire (FOSQ)11 and with the validated Symptoms of Nocturnal Obstruction and Related Events (SNORE25) questionnaire.12 Daytime sleepiness was measured with the validated Epworth Sleepiness Scale (ESS).13 Reaction times were measured with the validated Psychomotor Vigilance Task (PVT-192; Ambulatory Monitoring Inc, Ardsley, NY) with total test time of 10 minutes and stimulus interval of 2 to 10 seconds. The slowest reaction time (SRT) was defined as the mean 10% slowest reaction times, analyzed as 1/SRT to minimize the contribution of very long lapses. Median and fastest (mean 10% fastest) reaction times were also measured.14 Acoustic pharyngometry measurements were obtained but are not reported because of poor reproducibility of data. Long-term outcomes were measured at least 11 months after completion of TCRFTA treatments. Shortterm outcomes data are available only in the patients who were originally assigned to TCRFTA treatment and were measured at least 8 weeks after the completion of treatment. Short-term outcomes were compared with long-term outcomes to assess the stability of the observed short-term improvements.
Sleep Studies Sleep studies used the home Autoset PDS system (ResMed Corp, San Diego, CA), which was used at both screening baseline and long-term follow-up. Definitions of sleep study indices were published elsewhere.8 Intervention TCRFTA was performed with a radiofrequency generator (Gyrus-ENT, Memphis, TN) under local anesthesia in the medical office. Palate treatments consisted of 650 J delivered to midline and 325 J to each side, to create 3 nonoverlapping lesions per treatment session.
Data Management and Statistical Methods Data were collected on case report forms at each site. Copies were mailed to the sponsor’s data coordinators, who entered the data and visually checked for accuracy. The principal investigator at each treatment site verified data accuracy. Data also were checked statistically, and inconsistencies were resolved with the raw data at each site. Data are presented as the mean ⫾ SD. Effect sizes were calculated as (posttreatment mean – pretreatment mean)/(pretreatment SD) as per Kazis et al.15 A positive sign denotes improvement with treatment; a negative sign denotes worsening. Changes in outcome measures were analyzed by 1-sided paired t test for normally distributed variables and by 1-sided sign test for nonnormally distributed variables. One-
Otolaryngology– Head and Neck Surgery April 2005
632 STEWARD et al
Table 1. Baseline characteristics Variable Age (y) Sex (% male) Body Mass Index (kg/m2) Neck circumference (cm) Functional Outcome of Sleep Q SNORE25 Epworth Sleepiness Scale 1/Slowest reaction time (1/msec) Median reaction time (msec) Fastest reaction time (msec) Apnea-Hypopnea Index (events/h)* Apnea Index (events/h)*
⬍ 25 ⱕ 42 ⬎17.8 ⬍10 ⱖ 2.88 ⱕ 231 ⱕ191 ⬍5 ⬍5
Mean ⴞ SD
29 29 29 28 29 28 29 29 29 29 22 22
49 ⫾ 9 79 29 ⫾ 4 41 ⫾ 3 15.6 ⫾ 2.3 1.74 ⫾ 0.62 12.9 ⫾ 4.2 2.78 ⫾ 0.58 228 ⫾ 29 183 ⫾ 18 19 ⫾ 11 5⫾6
29-64 19-36 34-46 10.0-19.6 0.52-2.80 6-22 1.53-4.15 189-306 159-233 5-40 0-22
SD, standard deviation; SNORE25, Symptoms of Nocturnal Obstruction and Related Events questionnaire. *Based on home sleep study.
sided tests were used because improvement with treatment was expected.8,16 Changes in morphologic data were analyzed by 2-sided tests, because changes were not expected. Normality was tested by ShapiroWilk W test, Shapiro-Francia W= test, and combined skewness and kurtosis tests. A variable was considered nonnormal if it failed any 1 of these tests. Baseline and changes in outcome variables were reanalyzed after stratifying for significant covariates, and significant findings are presented. The data were analyzed with Stata 8/SE software (Stata Corp., College Station, TX). A P value of ⬍0.05 was considered statistically significant. RESULTS Baseline characteristics of the study sample are summarized in Table 1. In general, the subjects were overweight, middle-aged males with moderate OSAS and excessive daytime sleepiness. TCRFTA treatment is summarized in Table 2. Of the 29 patients who participated in long-term follow-up, 12 were originally randomized to TCRFTA treatment, 9 crossed over after nasal CPAP, and 8 crossed over after sham placebo. Relative to those originally randomized to TCRFTA treatment, crossover patients received fewer tongue treatment sessions (2.2 ⫾ 0.8 sessions versus 4.8 ⫾ 0.6 sessions, P ⬍ 0.001) and less total tongue energy (3500 ⫾ 1800 J versus 10,400 ⫾ 1300 J, P ⬍ 0.001). Median long-term follow-up after completion of TCRFTA treatment was 23 months (95% confidence interval, 19 – 26 months; range, 11 – 31 months). Median short-term follow-up in the original TCRFTA group was 9 weeks (95% confidence interval, 8 – 11 weeks; range, 8 – 26 weeks). Results of differences between pretreatment baseline and long-term follow-up are summarized in Table 3. All outcomes were improved at long-term
Table 2. Radiofrequency treatment summary Variable
Number of sessions Total energy (Joules)
3.3 ⫾ 1.5 6500 ⫾ 3800
2.0 ⫾ 0.6 2200 ⫾ 800
Data presented as mean ⫾ standard deviation.
follow-up, with quality of life, daytime sleepiness, median reaction time, and AHI each being statistically significant. These improvements were not related to changes in body mass index or neck circumference (each unchanged). The standardized magnitudes of the treatment effect for each outcome measure are presented graphically in Figure 1. By convention, a positive effect size denotes improvement in outcome measurement, such that treatment effects are considered negligible if less than 0.2, small if between 0.2 and 0.5, medium if between 0.5 and 0.8, and large if greater than 0.8.15 On average, OSAS-related quality of life, daytime sleepiness, and AHI were all significantly improved at extended follow-up, with large treatment effects. Reaction time testing was improved with small effect sizes. We stratified on tongue energy dose to examine low-dose (n ⫽ 17, 3700 ⫾ 1900 J) and high dose (n ⫽ 11, 10,700 ⫾ 600 J) subjects. The palate energy was comparable between these groups (2100 ⫾ 900 J versus 2400 ⫾ 300 J, respectively). The low-dose and highdose groups both improved comparably on all subjective measures (effect sizes, 0.67-1.10, all P ⬍ 0.05). The high-dose group had consistently greater benefits on the objective outcome measures (effect sizes, 0.320.98), with AHI and apnea index significant (P ⬍ 0.05) and slowest and median reaction times trending to significance (P ⬍ 0.10). The low-dose group had
Otolaryngology– Head and Neck Surgery Volume 132 Number 4
STEWARD et al 633
Table 3. Baseline versus long-term outcomes Outcome variables
Functional Outcome of Sleep Q SNORE25 Epworth Sleepiness Scale 1/Slowest reaction time (1/msec) Median reaction time (msec) Fastest reaction time (msec) Apnea-hypopnea index (events/h) Apnea index (events/h) Other Variables Neck circumference (cm) Body mass index (kg/m2)
29 28 29 27 27 27 20 18
1.8 ⫾ 1.9 ⫺0.69 ⫾ 0.61 ⫺3.4 ⫾ 3.9 0.15 ⫾ 0.51 ⫺6.1 ⫾ 18.0 ⫺2.9 ⫾ 12.2 ⫺10.4 ⫾ 11.3 ⫺2.8 ⫾ 6.2
0.81 1.11 0.81 0.28 0.25 0.16 0.87 0.41
⬍0.001 ⬍0.001 ⬍0.001 0.07 0.03 0.22 0.01 0.11
⫺0.2 ⫾ 1.2 0.0 ⫾ 1.4
Data presented as mean ⫾ standard deviation. SNORE25, Symptoms of Nocturnal Obstruction and Related Events questionnaire. *N ⫽ number of subjects with both baseline and long-term outcome data available for each variable. †Change ⫽ long-term outcome – baseline outcome. ‡Effect size ⫽ (long-term outcome – baseline outcome)/(baseline standard deviation). Positive effect size indicates improvement; negative indicates worsening. §P value based on one-sided paired t-test for comparison of means for normally distributed outcome variables or sign test for comparison of medians for non-normally distributed outcome variables (2-sided for other variables). P ⬍ 0.05 is significant (bold).
Thus, no relapse was observed for these clinically important outcomes. DISCUSSION
Fig 1. Long-term effect sizes after multilevel TCRFTA treatment. Effect size ⫽ (long-term outcome – baseline outcome)/(baseline SD). 1/SRT ⫽ slowest reaction time (reciprocal); RT ⫽ median reaction time; FRT ⫽ fastest reaction time; AI ⫽ apnea index. *Statistically significant (P ⬍ 0.05) effects.
mostly negligible to small benefits for objective outcomes (effect sizes, – 0.02 to 0.20), except in the case of AHI (effect size, 0.75), and none were statistically significant (all P ⬎ 0.15). Short-term outcome measurements were available only for subjects who were originally assigned TCRFTA treatment (n ⫽ 12) and only for quality of life, sleepiness, and reaction time outcomes. In this group, there were no significant changes from shortterm (median 9 weeks) to long-term (median 26 months) follow-up for these outcome measures (all P ⬎ 0.40). In fact, the point estimate of each outcome improved slightly at long-term follow-up, relative to short-term follow-up (effect size range, 0.07 – 0.28).
The results of this study suggest that multilevel (tongue and palate) TCRFTA results in prolonged subjective and objective improvements across treatment outcomes of OSAS in this multi-institutional series of patients. The prolonged symptomatic improvement in this series is consistent with that reported for TCRFTA treatment of the tongue base in a smaller pilot series of subjects with OSAS.9 These data further support the long-term effectiveness of TCRFTA treatment in subjects with OSAS, specifically with respect to quality of life, symptoms, vigilance, and respiratory parameters. There are several important potential limitations to this study. There is a potential selection bias among those choosing to participate in this follow-up study. Only 3 subjects were excluded because of additional treatment for OSAS after completion of TCRFTA, which suggests that this exclusion criterion introduced minimal selection bias. It was necessary to exclude these subjects to determine the long-term treatment effect of TCRFTA alone. It is possible that the research participants who declined crossover TCRFTA or who chose not to participate in this follow-up study had worse outcomes than did those who chose to participate. However, comparison of baseline (all subjects) and short-term outcomes (original TCRFTA subjects) indicated no significant differences between those who did and did not participate in long-term follow-up (analyses not shown). The case series study design limits our ability to detect the true long-term treatment effect. As shown in
Otolaryngology– Head and Neck Surgery April 2005
634 STEWARD et al
the parent randomized trial8 and another blinded TCRFTA trial,17 there are placebo and blinding effects, which cannot be controlled in a case series. The methodological ideal would be to follow both TCRFTA and placebo patients long-term. However, with demonstrated treatment benefit of TCRFTA relative to placebo at 9 weeks, it is unethical to leave placebo patients untreated for the long term. A goal of this study was to test the hypothesis that the proven treatment effect at 9 weeks persists over an extended time. The results from this case series support this hypothesis. A further limitation of this study is the use of home sleep studies rather than full in-laboratory studies. The home study provides sleep respiratory parameters that are limited, but sleep study variables were secondary outcomes from the outset.8 The improvement on respiratory parameters is consistent with the benefits observed for other outcome measures (reaction time, symptoms, and quality of life). The same home sleep study was used for both screening and baseline, which raises the risk of regression to the mean.18 However, comparison of the screening home sleep study with subsequent baseline polysomnography (used in the parent trial) revealed no consistent patterns of regression to the mean (analyses not shown). At long-term follow-up, we chose to measure respiratory outcome variables with the home sleep study to minimize patient burden and because of budgetary constraints. The small sample leaves little statistical power to detect important differences in stratified analyses. Thus, we are limited in our ability to identify important treatment or covariate features that impact long-term outcome. The nonrandomized study design further compromises our ability to test the independent treatment effect of these covariates, because confounding variables may distort the observed effect of these covariates. We did carry out various stratified analyses to begin to examine the influence of other variables on outcome. The subset analysis comparing short-term to longterm outcomes suggests that relapse did not occur. In fact, long-term outcomes were slightly better than short-term outcomes, despite stability of neck size and body mass index. The improvement at 26 months relative to 9 weeks was not statistically significant. Thus, these data do not indicate that outcomes continue to improve significantly more than 9 weeks after treatment is completed, but they do suggest that improvements at 9 weeks do not deteriorate by 26 months. There was a bimodal distribution of total energy delivered to the tongue. The low-dose subgroup had improvements in long-term subjective outcomes that were comparable to those in the high-dose subgroup. However, on every long-term objective outcome mea-
sured (ie, reaction times and sleep respiratory parameters), the high-dose subgroup had long-term improvement superior to that of the low-dose group. This pattern suggests a dose–response effect of the total tongue energy: a positive effect with a low dose and a greater effect with a high dose. Previous research has demonstrated incremental improvement after additional tongue and palate TCRFTA after tongue treatment alone.16 The current study suggests that additional tongue energy alone improves outcome. Subset analysis stratified on AHI (mild versus moderate to severe) suggested that both subgroups had significant improvements in the SNORE25 quality of life measurement (data not shown). Only the more severe OSAS group had large treatment effects and significant improvements in the other subjective outcomes and in the sleep respiratory outcomes. It is possible that more severe disease simply allows greater room for improvement. For example, the baseline apnea index was 0.9 events per hour in the mild subgroup and 10.1 events per hour in the moderate to severe subgroup. Thus, a change of ⫺0.9 was the greatest possible improvement in the mild subgroup, whereas a change of ⫺10.1 was possible in the moderate to severe subgroup. The original parent study demonstrated improved short-term outcomes in mild to moderate OSAS patients.8 The current study suggests that TCRFTA may also be useful in more severe OSAS patients, even though TCRFTA did not resolve OSAS in any of these subjects. Further prospective study will help delineate the role of TCRFTA in severe OSAS patients. CONCLUSION The results of this extended follow-up study suggest that multilevel TCRFTA provides significant prolonged improvements in OSAS-related quality of life, daytime sleepiness, psychomotor vigilance, and AHI. These data add to an enlarging body of evidence supporting the effectiveness of TCRFTA treatment for patients with OSAS.8,9,16,19-33 REFERENCES 1. Young T, Palta M, Dempsey J, et al. The occurrence of sleepdisordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-5. 2. Young T, Blustein J, Finn L, et al. Sleep-disordered breathing and motor vehicle accidents in a population-based sample of employed adults. Sleep 1997;20:608-13. 3. Krieger J, Meslier N, Lebrun T, et al. Accidents in obstructive sleep apnea patients treated with nasal continuous positive airway pressure: a prospective study. The Working Group ANTADIR, Paris and CRESGE, Lille, France. Association Nationale de Traitement a Domicile des Insuffisants Respiratoires. Chest 1997;112:1561-6. 4. Haraldsson PO, Carenfelt C, Lysdahl M, et al. Does uvulopalatopharyngoplasty inhibit automobile accidents? Laryngoscope 1995;105:657-61.
Otolaryngology– Head and Neck Surgery Volume 132 Number 4
5. Kribbs NB, Pack AI, Kline LR, et al. Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea. Am Rev Respir Dis 1993;147:887-95. 6. Mohsenin N, Mostofi MT, Mohsenin V. The role of oral appliances in treating obstructive sleep apnea. J Am Dent Assoc 2003;134:442-9. 7. Sher AE, Schechtman KB, Piccirillo JF. The efficacy of surgical modifications of the upper airway in adults with obstructive sleep apnea syndrome. Sleep 1996;19:156-77. 8. Woodson BT, Steward DL, Weaver EM, et al. A randomized trial of temperature-controlled radiofrequency, continuous positive airway pressure, and placebo for obstructive sleep apnea syndrome. Otolaryngol Head Neck Surg 2003;128:848-61. 9. Li KK, Powell NB, Riley RW, et al. Temperature-controlled radiofrequency tongue base reduction for sleep-disordered breathing: long-term outcomes. Otolaryngol Head Neck Surg 2002;127:230-4. 10. American Academy of Sleep Medicine Task Force. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep 1999;22:667-89. 11. Weaver TE, Laizner AM, Evans LK, et al. An instrument to measure functional status outcomes for disorders of excessive sleepiness. Sleep 1997;20:835-43. 12. Piccirillo JF, Gates GA, White DL, et al. Obstructive sleep apnea treatment outcomes pilot study. Otolaryngol Head Neck Surg 1998;118:833-44. 13. Johns MW. Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest 1993;103:30-6. 14. Jewett ME, Dijk DJ, Kronauer RE, et al. Dose-response relationship between sleep duration and human psychomotor vigilance and subjective alertness. Sleep 1999;22:171-9. 15. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27:S178-89. 16. Steward DL, Weaver EM, Woodson BT. A comparison of radiofrequency treatment schemes for obstructive sleep apnea syndrome. Otolaryngol Head Neck Surg 2004;130:579-85. 17. Powell NB, Zonato AI, Weaver EM, et al. Radiofrequency treatment of turbinate hypertrophy in subjects using continuous positive airway pressure: a randomized, double-blind, placebocontrolled clinical pilot trial. Laryngoscope 2001;111:1783-90. 18. Schechtman KB, Sher AE, Piccirillo JF. Methodological and statistical problems in sleep apnea research: the literature on uvulopalatopharyngoplasty. Sleep 1995;18:659-66. 19. Blumen MB, Dahan S, Fleury B, et al. Radiofrequency ablation for the treatment of mild to moderate obstructive sleep apnea. Laryngoscope 2002;112:2086-92.
STEWARD et al 635
20. Brown DJ, Kerr P, Kryger M. Radiofrequency tissue reduction of the palate in patients with moderate sleep-disordered breathing. J Otolaryngol 2001;30:193-8. 21. Coleman SC, Smith TL. Midline radiofrequency tissue reduction of the palate for bothersome snoring and sleep-disordered breathing: a clinical trial. Otolaryngol Head Neck Surg 2000;122:38794. 22. Nelson LM. Combined temperature-controlled radiofrequency tongue reduction and UPPP in apnea surgery. Ear Nose Throat J 2001;80:640-4. 23. Powell NB, Riley RW, Troell RJ, et al. Radiofrequency volumetric tissue reduction of the palate in subjects with sleepdisordered breathing. Chest 1998;113:1163-74. 24. Powell NB, Riley RW, Guilleminault C. Radiofrequency tongue base reduction in sleep-disordered breathing: a pilot study. Otolaryngol Head Neck Surg 1999;120:656-64. 25. Riley RW, Powell NB, Li KK, et al. An adjunctive method of radiofrequency volumetric tissue reduction of the tongue for OSAS. Otolaryngol Head Neck Surg 2003;129:37-42. 26. Sher AE, Flexon PB, Hillman D, et al. Temperature-controlled radiofrequency tissue volume reduction in the human soft palate. Otolaryngol Head Neck Surg 2001;125:312-8. 27. Stuck BA, Maurer JT, Hormann K. Tongue base reduction with radiofrequency tissue ablation: preliminary results after two treatment sessions. Sleep Breath 2000;4:155-62. 28. Stuck BA, Maurer JT, Hormann K. [Tongue base reduction with radiofrequency energy in sleep apnea]. HNO 2001;49:530-7. 29. Stuck BA, Maurer JT, Verse T, et al. Tongue base reduction with temperature-controlled radiofrequency volumetric tissue reduction for treatment of obstructive sleep apnea syndrome. Acta Otolaryngol 2002;122:531-6. 30. Woodson BT, Nelson L, Mickelson S, et al. A multi-institutional study of radiofrequency volumetric tissue reduction for OSAS. Otolaryngol Head Neck Surg 2001;125:303-11. 31. Friedman M, Ibrahim H, Lee G, et al. Combined uvulopalatopharyngoplasty and radiofrequency tongue base reduction for treatment of obstructive sleep apnea/hypopnea syndrome. Otolaryngol Head Neck Surg 2003;129:611-21. 32. Steward DL. Effectiveness of multilevel temperature controlled radiofrequency for obstructive sleep apnea. Laryngoscope 2004; 114:2073-84. 33. Fischer Y, Khan M, Mann WJ. Multilevel temperature-controlled radiofrequency therapy of soft palate, base of tongue, and tonsils in adults with obstructive sleep apnea. Laryngoscope 2003;113:1786-91.